Contrast-enhanced myocardial inversion time at the null point for detection of left ventricular myocardial fibrosis in patients with dilated and hypertrophic cardiomyopathy: A Pilot Study

American Journal of Roentgenology

Volumn 194, Issue 4, 2010, Pages

  Sueyoshi, Eijun ^a   Sakamoto, Ichiro ^a   Uetan, Masataka ^a  

^a NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cardiomyopathy; Delayed enhancement; MRI myocardial fibrosis

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GADOLINIUM PENTETATE; GADOLINIUM PENTETATE MEGLUMINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONGESTIVE CARDIOMYOPATHY; CONTRAST ENHANCEMENT; CONTROL GROUP; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DIAGNOSTIC PROCEDURE; DISEASE SEVERITY; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE FIBROSIS; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; LEFT VENTRICULAR MYOCARDIAL FIBROSIS; MALE; NON INVASIVE PROCEDURE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PILOT STUDY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

CARDIOMYOPATHY, DILATED; CARDIOMYOPATHY, HYPERTROPHIC; CASE-CONTROL STUDIES; CONTRAST MEDIA; FEMALE; FIBROSIS; GADOLINIUM DTPA; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PILOT PROJECTS; ROC CURVE; STATISTICS, NONPARAMETRIC; VENTRICULAR DYSFUNCTION, LEFT;

EID: 77950618804     PISSN: 0361803X     EISSN: None     Source Type: Journal    
DOI: 10.2214/AJR.09.3414     Document Type: Article

References (34)

1. Iles L, Pfluger H, Phrommintikul A, et al. Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced T1 mapping. J Am Coll Cardiol 2008; 52:1574-1580
2. Koelling TM, Chen RS, Lubwama RN, L'Italien GJ, Eagle KA. The expanding national burden of heart failure in the United States: the influence of heart failure in women. Am Heart J 2004; 147:74-78
3. Mann DL. Mechanisms and models in heart failure: a combinatorial approach. Circulation 1999; 100:999-1008
4. Kim RJ, Wu E, Rafael A, et al. The use of contrastenhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med 2000; 343:1445-1453
5. Kim RJ, Fieno DS, Parrish TB, et al. Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation 1999; 100:1992-2002
6. Assomull RG, Prasad SK, Lyne J, et al. Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. J Am Coll Cardiol 2006; 48:1977-1985
7. Bello D, Fieno DS, Kim RJ, et al. Infarct morphology identifies patients with substrate for sustained ventricular tachycardia. J Am Coll Cardiol 2005; 45:1104-1108
8. Bello D, Shah DJ, Farah GM, et al. Gadolinium cardiovascular magnetic resonance predicts reversible myocardial dysfunction and remodeling in patients with heart failure undergoing betablocker therapy. Circulation 2003; 108:1945-1953
9. Sparrow P, Messroghli DR, Reid S, Ridgway JP, Bainbridge G, Sivananthan MU. Myocardial T1 mapping for detection of left ventricular myocardial fibrosis in chronic aortic regurgitation: pilot study. AJR 2006; 187:1610; [web]W630-W635
10. Richardson P, McKenna W, Bristow M, et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology task force on the definition and classification of cardiomyopathies. Circulation 1996; 93:841-842
11. Messroghli DR, Plein S, Higgins DM, et al. Human myocardium: single-breath-hold MR T1 mapping with high spatial resolution-reproducibility study. Radiology 2006; 238:1004-1012
12. Fleiss JL. Statistical methods for rates and proportions, 2nd ed. New York, NY: Wiley, 1981:14-15
13. Zou KH, Tuncali K, Silverman SG. Correlation and simple linear regression. Radiology 2003; 227:617-622
14. O'Neill JO, McCarthy PM, Brunken RC, et al. PET abnormalities in patients with nonischemic cardiomyopathy. J Card Fail 2004; 10:244-249
15. Knaapen P, Boellaard R, Götte MJ, et al. Perfusable tissue index as a potential marker of fibrosis in patients with idiopathic dilated cardiomyopathy. J Nucl Med 2004; 45:1299-1304
16. Huber AM, Schoenberg SO, Hayes C, et al. Phasesensitive inversion-recovery MR imaging in the detection of myocardial infarction. Radiology 2005; 237:854-860
17. Oshinski JN, Yang Z, Jones JR, Mata JF, French BA. Imaging time after Gd-DTPA injection is critical in using delayed enhancement to determine infarct size accurately with magnetic resonance imaging. Circulation 2001; 104:2838-2842
18. Klein C, Nekolla SG, Bengel FM, et al. Assessment of myocardial viability with contrast enhanced magnetic resonance imaging: comparison with positron emission tomography. Circulation 2002; 105:162-167
19. McCrohon JA, Moon JC, Prasad SK, et al. Differentiation of heart failure related to dilated cardiomyopathy and coronary artery disease using gadolinium-enhanced cardiovascular magnetic resonance. Circulation 2003; 108:54-59
20. Maron BJ. Sudden death in young athletes. N Engl J Med 2003; 349:1064-1075
21. Maron BJ, McKenna WJ, Danielson GK, et al. ACC/ESC clinical expert consensus document on hypertrophic cardiomyopathy: a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee forPractice Guidelines (Committee to Develop an Expert Consensus Document on Hypertrophic Cardiomyopathy). J Am Coll Cardiol 2003; 42: 1687-1713
22. Elliott P, McKenna WJ. Hypertrophic cardiomyopathy. Lancet 2004; 363:1881-1891
23. Maron BJ, Shirani J, Poliac LC, Mathenge R, Roberts WC, Mueller FO. Sudden death in young competitive athletes: clinical, demographic, and pathological profiles. JAMA 1996; 276:199-204
24. Maron BJ, Wolfson JK, Epstein SE, et al. Intramural ("small vessel") coronary artery disease in hypertrophic cardiomyopathy. J Am Coll Cardiol 1986; 8:545-557
25. Tanaka M, Fujiwara H, Onodera T, Wu DJ, Hamashima Y, Kawai C. Quantitative analysis of myocardial fibrosis in normals, hypertensive hearts, and hypertrophic cardiomyopathy. Br Heart J 1986; 55:575-581
26. Factor SM, Butany J, Sole MJ, Wigle ED, Williams WC, Rojkind M. Pathologic fibrosis and matrix connective tissue in the subaortic myocardium of patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 1991; 17:1343-1351
27. Basso C, Thiene G, Corrado D, Buja G, Melacini P, Nava A. Hypertrophic cardiomyopathy and sudden death in the young: pathologic evidence of myocardial ischemia. Hum Pathol 2000; 31:988-998
28. Shirani J, Pick R, Roberts WC, Maron BJ. Morphology and significance of left ventricular collagen network in young patients with hypertrophic cardiomyopathy and sudden cardiac death. J Am Coll Cardiol 2000; 35:36-44
29. Varnava AM, Elliott PM, Baboonian C, Davison F, Davies MJ, McKenna WJ. Hypertrophic cardiomyopathy: histopathological features of sudden death in cardiac troponin T disease. Circulation 2001; 104:1380-1384
30. Hurwitz JL, Josephson ME. Sudden cardiac death in patients with chronic coronary heart disease. Circulation 1992; 85:I43-I49
31. Josephson ME. Recurrent ventricular tachycardias. In: Josephson ME, ed. Clinical cardiac electrophysiology. Philadelphia, PA: Lippincott Williams & Wilkins, 2002:433-445
32. Dec GW, Fuster V. Idiopathic dilated cardiomyopathy. N Engl J Med 1994; 331:1564-1575
33. Ikram H, Williamson HG, Won M, Crozier IG, Wells EJ. The course of idiopathic dilated cardiomyopathy in New Zealand. Br Heart J 1987; 57: 521-527
34. Goldberger JJ, Cain ME, Hohnloser SH, et al. AHA/ACC Foundation/Heart Rhythm Society scientific statement on noninvasive risk stratification techniques for identifying patients at risk for sudden cardiac death: a scientific statement from the American Heart Association Council on Clinical Cardiology Committee on Electrocardiography and Arrhythmias and Council on Epidemiology and Prevention. Circulation 2008; 118:1497-1518